BREAKING NEWS
This content is not available in your region

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo   -   Copyright  Brendan McDermid(Reuters)
Text size Aa Aa

(Reuters) – AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.